IRUXOL MONO OINTMENT

Indications

• Debridement of necrotic tissue
• Facilitation of wound healing
• Surgical procedures requiring tissue removal
• Management of burns and chronic ulcers

Dosage

Children: Refer to specific clinical guidelines and product labeling for dosing information, as it may vary based on the indication and local protocols.

Adults: Refer to specific clinical guidelines and product labeling for dosing information, as it may vary based on the indication and local protocols.

Mechanism of action

Clostridiopeptidase acts by cleaving peptide bonds in proteins, which leads to the breakdown of collagen and other extracellular matrix components. This enzymatic activity promotes the liquefaction of necrotic tissue, facilitating its removal and improving healing outcomes. The enzyme selectively targets peptide bonds in collagen, enhancing tissue remodeling and repair.

Pharmacodynamics

The pharmacodynamics of clostridiopeptidase are characterized by its ability to degrade structural proteins, which aids in the debridement of wounds. By breaking down collagen and other proteins, it allows for improved cellular access to the wound site, enhancing the healing process. The activity of clostridiopeptidase can result in reduced inflammation and improved tissue regeneration.

Pharmacokinetics

Clostridiopeptidase is administered locally to the site of application, thus its systemic absorption is minimal. The pharmacokinetics may vary based on the method of administration and the specific surgical procedure. The enzyme is generally rapidly inactivated in the bloodstream due to the presence of protease inhibitors. The duration of action is typically limited to the time it remains at the site of application and is influenced by local conditions such as pH and temperature.

Pregnancy

There is insufficient data on the use of clostridiopeptidase in pregnancy. Caution is advised.

Breast-feeding

There is limited information on the excretion of clostridiopeptidase in human milk. Caution is advised when administering to nursing mothers.

Storage

Store at controlled room temperature, away from light and moisture. Keep out of reach of children.

Indications

• Dupuytren's contracture
• Chronic wounds
• Fasciitis

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Collagenase acts by hydrolyzing peptide bonds in collagen, leading to the degradation of collagen fibers. This enzymatic action promotes the dissolution of collagen-rich tissues and helps in the remodeling process, allowing for improved tissue flexibility and function.

Pharmacodynamics

Collagenase exhibits a localized effect at the site of administration, leading to the breakdown of collagenous tissue. Its action reduces the stiffness and contracture associated with conditions such as Dupuytren's contracture, enhancing the range of motion in affected joints. The effectiveness of collagenase is influenced by the concentration of the enzyme and the duration of treatment.

Pharmacokinetics

Collagenase is typically administered locally, and its pharmacokinetics can vary depending on the formulation and method of administration. The enzyme is rapidly inactivated in systemic circulation, minimizing systemic exposure. The duration of action is influenced by the local tissue environment and the presence of other factors that may affect collagen turnover.

Contra-indications

• Hypersensitivity to collagenase or any excipients in the formulation
• Active infection in the wound area

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Allergic reactions (rash, itching, anaphylaxis)
• Fever
• Chills
• Nausea
• Diarrhea

Interactions

• Anticoagulants may increase the risk of bleeding at the injection site
• Concurrent use with other enzymatic agents should be approached with caution

Precautions

• Use with caution in patients with a history of hypersensitivity or allergic reactions
• Monitor the wound for signs of infection post-treatment
• Assess the patient for potential bleeding risks

Pregnancy

No adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether collagenase is excreted in human milk. Caution should be exercised when administering to a nursing mother.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Collagenase injection solution

Indications

• HIV infection
• Chronic hepatitis C
• Certain cancers
• Cystic fibrosis
• Inhibition of pathological proteases in various diseases

Dosage

Children: Refer to the BNF for Children for appropriate paediatric dosing information, as it varies based on age, weight, and specific indications.

Adults: Refer to specific product guidelines and the BNF for dosing information, as it varies among different protease inhibitors.

Mechanism of action

Protease inhibitors work by binding to the active site of proteases, preventing them from cleaving precursor proteins into their active forms. This inhibition disrupts the lifecycle of viruses, such as HIV, by blocking the production of infectious viral particles. In cancer therapy, inhibiting proteases can interfere with tumor growth and metastasis by affecting the processing of proteins involved in cell division and apoptosis.

Pharmacodynamics

The pharmacodynamic effects of protease inhibitors vary depending on the specific enzyme targeted. In the case of HIV treatment, protease inhibitors lead to a decrease in viral load and an increase in CD4 cell counts, contributing to improved immune function. These inhibitors can also have effects on metabolic pathways, leading to side effects such as hyperlipidemia and insulin resistance.

Pharmacokinetics

Protease inhibitors are typically administered orally and exhibit variable absorption profiles. Their distribution is influenced by plasma protein binding, and they may have significant first-pass metabolism. The elimination half-lives can vary widely between different protease inhibitors, often requiring dose adjustments based on drug interactions and patient-specific factors. Certain protease inhibitors are substrates of cytochrome P450 enzymes, which may lead to significant drug-drug interactions.

Adverse effects

• Nausea
• Diarrhea
• Headache
• Fatigue
• Skin rash
• Hyperlipidemia
• Insulin resistance

Interactions

• Caution with concurrent use of certain antihypertensives due to potential for increased blood pressure
• May interact with anticoagulants, increasing the risk of bleeding
• Can affect the metabolism of other drugs processed by CYP450 enzymes

Precautions

• Monitor liver function tests regularly due to potential hepatotoxicity
• Assess for signs of opportunistic infections in immunocompromised patients
• Use caution in patients with a history of pancreatitis

Pregnancy

The use of protease inhibitors during pregnancy should be considered only if the potential benefits outweigh the risks, as there may be limited data on their safety.

Breast-feeding

It is generally recommended to avoid breastfeeding while on protease inhibitors due to potential transmission of the drug in breast milk.

Storage

Store at room temperature, away from moisture and heat. Ensure the medication is kept in its original container to maintain stability.

Formulations

• Tablets
• Capsules
• Oral solutions